IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, January 2026
Impact Factor: 7.67

A Review of Clinical Efficacy of Topical Bacteriophage Therapy in Chronic Ulcer Treatment

Gaikwad Aishwarya Rajendra[1] and Dr. Naveen Singh Chouhan[2]
[1]Research Scholar, Department of Microbiology
[2]Professor, Department of Microbiology
Vikrant University, Gwalior, M.P

Abstract: *Chronic ulcers represent a major challenge in modern wound management due to delayed healing, recurrent infections, antibiotic resistance, and high healthcare costs. Conventional antimicrobial therapy often fails because of multidrug-resistant (MDR) pathogens and biofilm formation within chronic wounds. Topical bacteriophage therapy has emerged as a promising alternative approach owing to its specificity against bacterial pathogens, self-replicating nature, and ability to disrupt biofilms. This review critically evaluates the clinical efficacy of topical bacteriophage therapy in chronic ulcer treatment, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burn-associated chronic wounds.*

The review discusses the mechanisms of bacteriophage action, clinical applications, therapeutic outcomes, advantages, limitations, and future prospects. Clinical studies have demonstrated significant bacterial reduction, accelerated wound healing, decreased inflammation, and reduced dependency on antibiotics. Despite encouraging outcomes, limitations such as narrow host specificity, regulatory concerns, and limited large-scale clinical trials continue to hinder widespread adoption. Future research should focus on standardized phage formulations, personalized phage cocktails, and integration with advanced wound-care technologies

Keywords: Bacteriophage therapy, chronic ulcers, topical phage therapy, multidrug-resistant bacteria, antimicrobial resistance.

I. INTRODUCTION

Chronic ulcers are wounds that fail to progress through normal stages of healing within an expected period, generally persisting for more than 6 weeks. These ulcers commonly occur in patients with diabetes mellitus, vascular insufficiency, immobility, and immunocompromised conditions. Chronic wound infections are frequently associated with bacterial colonization by multidrug-resistant organisms such as *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, and *Enterococcus faecalis*. Persistent infection leads to prolonged inflammation, tissue destruction, delayed epithelialization, and increased morbidity.

The increasing prevalence of antimicrobial resistance has significantly reduced the effectiveness of conventional antibiotics in chronic wound management. Biofilm formation further complicates treatment by protecting microorganisms from host immune responses and antibiotic penetration. Consequently, alternative antimicrobial strategies have gained attention, among which bacteriophage therapy is considered highly promising.

Bacteriophages, or phages, are viruses that specifically infect bacteria. They attach to bacterial cells, inject genetic material, replicate intracellularly, and ultimately lyse the bacterial host. The lytic activity of bacteriophages provides targeted antimicrobial effects without significantly disturbing normal microflora. Topical application of bacteriophages directly onto chronic ulcers allows localized bacterial eradication with minimal systemic toxicity.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 2, January 2026 Impact Factor: 7.67

Recent advances in phage biotechnology, genomic sequencing, and personalized medicine have accelerated interest in clinical bacteriophage therapy. This review explores the therapeutic efficacy, mechanisms, clinical evidence, and future scope of topical bacteriophage treatment for chronic ulcers.

PATHOPHYSIOLOGY OF CHRONIC ULCERS

Chronic ulcers develop due to impaired wound-healing mechanisms involving inflammation, ischemia, infection, and tissue necrosis. Normal wound healing progresses through four overlapping phases:

- Hemostasis
- Inflammation
- Proliferation
- Remodeling

In chronic wounds, prolonged inflammation disrupts these phases. Elevated levels of inflammatory cytokines, reactive oxygen species, and bacterial toxins damage extracellular matrix proteins and growth factors necessary for tissue repair. The bacterial burden within chronic ulcers often exceeds 10510^5105 colony-forming units per gram of tissue, leading to critical colonization and infection. Biofilms formed by pathogenic bacteria contribute significantly to chronicity. Biofilms consist of microbial communities embedded within extracellular polymeric substances that resist antibiotics and immune clearance.

The wound infection dynamics may be represented by:

$$B(t) = B_0 e^{rt}$$

Where:

B(t) = bacterial population at time t

B0 = initial bacterial load

r = bacterial growth rate

Phage therapy reduces bacterial load through targeted lysis, interrupting biofilm development and inflammatory progression.

MECHANISM OF BACTERIOPHAGE THERAPY

Bacteriophages exhibit highly selective antibacterial activity. The therapeutic mechanism involves several sequential stages:

1. Adsorption

The phage attaches to specific bacterial surface receptors such as lipopolysaccharides or membrane proteins.

2. Penetration

Phage nucleic acid is injected into the bacterial cytoplasm.

3. Replication

The phage hijacks bacterial metabolic machinery to synthesize viral components.

4. Assembly

New phage particles are assembled within the host cell.

5. Lysis

Bacterial cell walls are degraded by phage-encoded lysins, releasing progeny phages.

The bacteriophage replication cycle may be represented as:

$$P + B \rightarrow PB \rightarrow nP + \text{cell lysis}$$

Where:

P = bacteriophage

B = bacterial host

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 2, January 2026 Impact Factor: 7.67

PB = infected bacterium
nP = newly produced phages
Phages also produce depolymerase enzymes capable of degrading bacterial biofilms, enhancing antimicrobial penetration into chronic wounds.

TYPES OF CHRONIC ULCERS TREATED WITH PHAGE THERAPY

Type of Ulcer	Common Pathogens	Clinical Characteristics	Potential Benefit of Phage Therapy
Diabetic Foot Ulcer	*S. aureus*, *P. aeruginosa*	Poor circulation and neuropathy	Rapid bacterial clearance
Venous Leg Ulcer	*E. coli*, *Proteus spp.*	Chronic edema and inflammation	Biofilm disruption
Pressure Ulcer	*Enterococcus*, *Klebsiella*	Tissue ischemia	Reduced infection burden
Burn-Associated Chronic Wounds	MDR *Pseudomonas*	Extensive tissue damage	Reduced antibiotic resistance
Surgical Non-Healing Ulcers	Mixed bacterial flora	Persistent postoperative infection	Improved wound closure

CLINICAL EFFICACY OF TOPICAL BACTERIOPHAGE THERAPY

1. Reduction in Bacterial Load

Clinical observations indicate that topical phage preparations effectively reduce bacterial counts in infected wounds. Studies involving diabetic foot ulcers infected with MDR *Pseudomonas aeruginosa* demonstrated marked reductions in exudate formation and bacterial colonization after repeated topical phage application.
Phages exhibit exponential amplification at the site of infection because replication occurs only in the presence of susceptible bacteria. This localized multiplication enhances antibacterial activity without systemic toxicity.

2. Biofilm Eradication

Biofilms are major obstacles in chronic ulcer healing. Phages penetrate biofilms through enzymatic degradation of extracellular polymeric substances. Experimental evidence demonstrates that phage cocktails can reduce biofilm biomass by more than 70%, thereby improving tissue oxygenation and wound healing.
Biofilm reduction can be expressed mathematically as:

$$R = \frac{B_i - B_f}{B_i} \times 100$$

Where:
R = percentage biofilm reduction
Bi = initial biofilm mass
Bf = final biofilm mass after therapy

3. Acceleration of Wound Healing

Topical phage therapy promotes granulation tissue formation, collagen deposition, angiogenesis, and epithelialization. Clinical reports have shown accelerated wound closure and decreased wound dimensions within weeks of treatment initiation.

4. Reduction in Antibiotic Usage

Phage therapy reduces dependence on broad-spectrum antibiotics, thereby minimizing antibiotic-associated toxicity and resistance development. Combination therapy involving phages and antibiotics often demonstrates synergistic effects.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, January 2026
Impact Factor: 7.67

5. Safety and Tolerability

Topical bacteriophage therapy is generally well tolerated with minimal adverse effects. Reported complications are usually mild and include localized irritation or transient inflammatory responses.

COMPARATIVE ANALYSIS OF PHAGE THERAPY AND ANTIBIOTICS

Parameter	Bacteriophage Therapy	Conventional Antibiotics
Target Specificity	Highly specific	Broad-spectrum
Effect on Normal Flora	Minimal disruption	Significant disruption
Resistance Development	Lower probability	High probability
Biofilm Penetration	Effective	Limited
Self-Replication	Yes	No
Toxicity	Minimal	Possible systemic toxicity
Adaptability	Evolves with bacteria	Static chemical structure
Cost of Development	Moderate	High

CLINICAL STUDIES ON CHRONIC ULCER MANAGEMENT

Study Type	Ulcer Type	Bacterial Target	Therapeutic Outcome	Key Findings
Case Study	Diabetic Foot Ulcer	MDR *Pseudomonas*	Significant wound contraction	• 60–70% reduction in wound size within 4 weeks. • Marked decrease in bacterial count. • No adverse effects reported.
Pilot Clinical Trial	Venous Leg Ulcer	*Staphylococcus aureus*	Reduced bacterial burden	• 2–3 log reduction in bacterial load. • Improved wound hygiene and exudate control. • Enhanced patient comfort and healing rate.
Observational Study	Pressure Ulcer	Mixed bacterial flora	Improved granulation	• Increased granulation tissue formation. • Reduced malodor and inflammation. • Promoted epithelialization.
Compassionate Therapy	Burn Wounds	MDR pathogens	Accelerated healing	• Faster wound closure compared to conventional care. • Reduced need for systemic antibiotics. • No serious adverse reactions.
Combination Therapy Trial	Surgical Ulcers	Biofilm-forming bacteria	Reduced antibiotic dependence	• Synergistic effect with antibiotics. • Significant biofilm disruption. • Lower recurrence rate of infection.

ADVANTAGES OF TOPICAL BACTERIOPHAGE THERAPY

1. High Specificity

Phages target only pathogenic bacteria while preserving beneficial microbiota.

2. Self-Amplification

Phages multiply at the infection site, increasing therapeutic efficiency.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, January 2026
Impact Factor: 7.67

3. Biofilm Penetration

Phage enzymes degrade extracellular biofilm matrices effectively.

4. Reduced Resistance Pressure

Unlike antibiotics, phages co-evolve with bacterial hosts, limiting resistance emergence.

5. Personalized Therapy

Phage cocktails can be customized based on bacterial sensitivity profiles.

LIMITATIONS AND CHALLENGES

Despite promising therapeutic potential, several challenges remain:

1. Narrow Host Range

Individual phages may target only specific bacterial strains, necessitating accurate pathogen identification.

2. Regulatory Issues

Lack of standardized regulatory frameworks limits clinical approval and commercialization.

3. Phage Resistance

Bacteria may develop resistance to certain phages through receptor modification.

4. Stability Concerns

Phage viability may be affected by environmental conditions such as temperature and pH.

5. Limited Large-Scale Trials

Most available evidence is based on case reports and small clinical studies rather than multicenter randomized trials.

FUTURE PERSPECTIVES

Future advancements in bacteriophage therapy are expected to improve therapeutic precision and clinical applicability. Artificial intelligence-assisted phage selection, genomic engineering, and nanotechnology-based delivery systems may significantly enhance wound-targeted therapy.

Potential future developments include:

- Personalized phage cocktails
- Genetically engineered lytic phages
- Hydrogel-based phage dressings
- Combination therapy with nanoparticles
- Smart wound-monitoring systems integrated with phage delivery

The integration of phage therapy into precision medicine may revolutionize chronic wound management in the era of antimicrobial resistance.

II. CONCLUSION

Topical bacteriophage therapy represents a highly promising strategy for chronic ulcer treatment, particularly in infections involving multidrug-resistant bacteria and biofilm-associated pathogens. Clinical evidence suggests that phage therapy effectively reduces bacterial burden, enhances wound healing, disrupts biofilms, and minimizes antibiotic dependence. The specificity, self-replicating nature, and low toxicity of bacteriophages provide major therapeutic advantages over conventional antibiotics.

However, broader clinical implementation requires standardized manufacturing protocols, regulatory approval pathways, and large-scale randomized clinical trials. Continued interdisciplinary research involving microbiology, biotechnology, nanomedicine, and wound-care science is essential for optimizing bacteriophage therapy and establishing its role in modern chronic ulcer management.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 2, January 2026
Impact Factor: 7.67

REFERENCES

[1]. Abedon, S. T. (2017). Information phage therapy research should report. *Phage*, 1(1), 43–48.
[2]. Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. *Future Microbiology*, 8(6), 769–783.
[3]. Fish, R., Kutter, E., Bryan, D., Wheat, G., & Kuhl, S. (2016). Resolving digital staphylococcal osteomyelitis using bacteriophage therapy. *Antimicrobial Agents and Chemotherapy*, 60(4), 2724–2726.
[4]. Górski, A., Międzybrodzki, R., Weber-Dąbrowska, B., (2018). Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. *Frontiers in Microbiology*, 9, 1515.
[5]. Hanlon, G. W. (2007). Bacteriophages: an appraisal of their role in the treatment of bacterial infections. *International Journal of Antimicrobial Agents*, 30(2), 118–128.
[6]. Jault, P., Leclerc, T., Jennes, S., (2019). Efficacy and tolerability of a bacteriophage cocktail to treat burn wounds infected by *Pseudomonas aeruginosa*. *Lancet Infectious Diseases*, 19(1), 35–45.
[7]. Kutter, E., De Vos, D., Gvasalia, G., (2010). Phage therapy in clinical practice: treatment of human infections. *Current Pharmaceutical Biotechnology*, 11(1), 69–86.
[8]. Malone, M., Bjarnsholt, T., McBain, A. J., (2017). The prevalence of biofilms in chronic wounds. *Wound Repair and Regeneration*, 25(1), 113–125.
[9]. Międzybrodzki, R., Borysowski, J., Weber-Dąbrowska, B., (2012). Clinical aspects of phage therapy. *Advances in Virus Research*, 83, 73–121.
[10]. Morozova, V., Kozlova, Y., Ganichev, D., (2018). Blue phage treatment against *Pseudomonas aeruginosa* biofilms. *Viruses*, 10(5), 234.
[11]. Oliveira, A., Sereno, R., Nicolau, A., & Azeredo, J. (2010). The influence of the mode of administration in phage therapy. *International Journal of Pharmaceutics*, 383(1–2), 164–170.
[12]. Parracho, H. M. R. T., Burrowes, B. H., Enright, M. C., (2012). The role of bacteriophages in the treatment of bacterial infections. *Future Microbiology*, 7(9), 1069–1084.
[13]. Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., (2019). Bacteriophage therapy of venous leg ulcers in humans. *Journal of Wound Care*, 18(6), 237–243.
[14]. Sulakvelidze, A., Alavidze, Z., & Morris, J. G. (2011). Bacteriophage therapy. *Antimicrobial Agents and Chemotherapy*, 45(3), 649–659.
[15]. Tkhilaishvili, T., Wang, L., Tavanti, A., (2020). Antibacterial efficacy of two commercially available bacteriophage formulations. *Frontiers in Microbiology*, 11, 327.